Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESO-101 in adult patients with eosinophilic esophagitis
2020-000082-16Phase 2Completed
- Sponsor
- EsoCap AG
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing ESO-101 with Placebo (2 arms). Primary endpoint: Absolute change in peak eosinophil count from baseline to end of treatment. Started Jul 2020; status: completed.
02
Drugs
ESO-101
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on 2020-000082-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000082-16.